|
Recent update to Celgene's Pomalidomide...
Here's a link update for next-generation immunomodulator Pomalidomide in an upcoming review of the drug in relapsed refractory multiple myeloma patients. 
"The follow-on to the blockbuster Revlimid (lenalidomide) is slated for a review by FDA’s Oncologic Drugs Advisory Committee on Nov. 8 for use in combination with dexamethasone for patients with relapsed and refractory multiple myeloma who received at least two prior regimens of benefit, including lenalidomide and the proteasome inhibitor bortezomib (Millennium: The Takeda Oncology Co.’s Velcade), and nevertheless progressed."
http://www.oncologystat.com/news/Cel..._in_Wings.html
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30%  ) 47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1).
|